Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sue Stephens

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Mabs|March 2, 2010
Certolizumab pegolNiti Goel, Sue Stephens
Toxicological Sciences : an Official Journal of the Society of Toxicology|April 22, 2011
The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab' monoclonal antibodyIan Wakefield, Sue Stephens, Roly Foulkes, et al.
Pediatric Dermatology|June 6, 2003
Paraneoplastic pemphigus with bronchiolitis obliterans in a childWinnie A Mar, Robin Glaesser, Kristin Struble, et al.
Inflammatory Bowel Diseases|July 20, 2007
Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agentsAndrew Nesbitt, Gianluca Fossati, Marianne Bergin, et al.
Pediatric Blood & Cancer|October 30, 2015
Skin Cancer Surveillance Behaviors Among Childhood Cancer SurvivorsJerod L Stapleton, Kristina L Tatum, Katie A Devine, et al.
Cancer Immunology, Immunotherapy : CII|February 5, 2005
Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22John F DiJoseph, Andrew Popplewell, Simon Tickle, et al.
Blood|November 15, 2003
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignanciesJohn F DiJoseph, Douglas C Armellino, Erwin R Boghaert, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Mabs|March 2, 2010
Certolizumab pegolNiti Goel, Sue Stephens
Toxicological Sciences : an Official Journal of the Society of Toxicology|April 22, 2011
The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab' monoclonal antibodyIan Wakefield, Sue Stephens, Roly Foulkes, et al.
Pediatric Dermatology|June 6, 2003
Paraneoplastic pemphigus with bronchiolitis obliterans in a childWinnie A Mar, Robin Glaesser, Kristin Struble, et al.
Inflammatory Bowel Diseases|July 20, 2007
Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agentsAndrew Nesbitt, Gianluca Fossati, Marianne Bergin, et al.
Pediatric Blood & Cancer|October 30, 2015
Skin Cancer Surveillance Behaviors Among Childhood Cancer SurvivorsJerod L Stapleton, Kristina L Tatum, Katie A Devine, et al.
Cancer Immunology, Immunotherapy : CII|February 5, 2005
Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22John F DiJoseph, Andrew Popplewell, Simon Tickle, et al.
Blood|November 15, 2003
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignanciesJohn F DiJoseph, Douglas C Armellino, Erwin R Boghaert, et al.
Pageof 1